News

The agreement between Avidas and Crown includes development collaboration and additional dermatology products. Financial terms of the transaction were not disclosed. The first products to be launched by

REG1 is a two-component system composed of an aptamer-based anticoagulant, RB006, and its matched, active reversal agent, RB007, which specifically binds to and neutralizes RB006. The Phase IIa

The study was initiated in July 2008 in bronchiectasis centers in the UK and enrolled a total of 36 patients as planned. The subjects were randomized to two

According to Dr Reddy’s Laboratories, EpiCeram emulsion provides an optimal 3:1:1 ratio of ceramides, free fatty acids and cholesterol to help repair the damaged skin barrier in order

In the study, six end-stage renal disease (ESRD) patients received a series of three, four-hour Hemopurifier treatments every other day during the course of one week. The treatment

Omrix said that the European Medicines Agency’s (EMEA’s) approval permits Evicel to be marketed in Europe under the following indication: “As a supportive treatment in surgery where standard

This agreement defines the terms of a development that will bring together GE’s Mac-Lab IT with first of its kind wireless measurement of Fractional Flow Reserve (FFR) from

Recently cleared by the FDA, Discovery PET/CT 600 is part of GE’s Discovery family of scanners designed to enable earlier detection and accurate monitoring of disease with molecular

As part of the agreement, Hospira has acquired additional assets related to the EndoTool business, including the MD Scientific headquarters in Charlotte, North Carolina and the employees supporting